AstraZeneca's Investigational Hypertension Drug Shows Significant Blood Pressure Control In Pivotal Trial

Core Insights - AstraZeneca Plc has released full data from the Bax24 Phase 3 trial, demonstrating the efficacy of baxdrostat in reducing ambulatory systolic blood pressure (SBP) in patients with resistant hypertension [1][2][3] Efficacy Results - Baxdrostat showed a statistically significant reduction in ambulatory 24-hour average SBP compared to placebo at 12 weeks, with a placebo-adjusted reduction of 14.0 mmHg [4] - The drug was effective throughout the 24-hour period, particularly during early morning hours when hypertension patients are at higher risk for cardiovascular events [2][4] - A significantly higher percentage of patients treated with baxdrostat (71%) achieved an ambulatory 24-hour average SBP of less than 130 mmHg compared to 17% in the placebo group [5] Safety and Tolerability - Baxdrostat was generally well tolerated, with a safety profile consistent with previous trials, including the BaxHTN trial [4][5] Presentation and Acquisition - Full results from the Bax24 trial were presented at the American Heart Association (AHA) Scientific Sessions 2025 [5] - AstraZeneca acquired baxdrostat through its purchase of CinCor Pharma, Inc. in February 2023 [5] Market Reaction - Following the announcement, AstraZeneca's stock increased by 2.49%, reaching $86.68 [5]